ARWR vs MDGL
Arrowhead Pharmaceuticals, Inc. and Madrigal Pharmaceuticals, Inc., both Healthcare
Madrigal Pharmaceuticals, Inc. is the larger company at $12B against $11B. Over the past year ARWR returned +105% against +7.3% for MDGL. The RyuScore puts ARWR ahead, 18 against 11 out of 100.
| Figure | ARWR | MDGL |
|---|---|---|
| Last close | $62.78 | $472 |
| Market cap | $11B | $12B |
| 1-year return | +105% | +7.3% |
| 5-year return | +0.4% | +496% |
| RyuScoresector-relative, 1–10 | 18/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Arrowhead Pharmaceuticals, Inc.
Revenue of $75M in Q3 2026, net income null.
Madrigal Pharmaceuticals, Inc.
Revenue of $364M in Q2 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.